Document Detail

Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives.
Jump to Full Text
MedLine Citation:
PMID:  22131946     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Migraine is one of the commonest neurological disorders. Despite intensive research, its exact pathomechanism is still not fully understood and effective therapy is not always available. One of the key molecules involved in migraine is glutamate, whose receptors are found on the first-, second- and third-order trigeminal neurones and are also present in the migraine generators, including the dorsal raphe nucleus, nucleus raphe magnus, locus coeruleus and periaqueductal grey matter. Glutamate receptors are important in cortical spreading depression, which may be the electrophysiological correlate of migraine aura. The kynurenine metabolites, endogenous tryptophan metabolites, include kynurenic acid (KYNA), which exerts a blocking effect on ionotropic glutamate and α7-nicotinic acetylcholine receptors. Thus, KYNA and its derivatives may act as modulators at various levels of the pathomechanism of migraine. They can give rise to antinociceptive effects at the periphery, in the trigeminal nucleus caudalis, and may also act on migraine generators and cortical spreading depression. The experimental data suggest that KYNA or its derivatives might offer a novel approach to migraine therapy.
Authors:
Annamária Fejes; Arpád Párdutz; József Toldi; László Vécsei
Related Documents :
18714376 - Rapid reversal of chondroitin sulfate proteoglycan associated staining in subcompartmen...
9858686 - Requirement for epha receptor signaling in the segregation of xenopus third and fourth ...
17945206 - Ephrin-b2 immunoreactivity distribution in adult mouse brain.
17145186 - The "scg10-like protein" sclip is a novel regulator of axonal branching in hippocampal ...
16141516 - Metabolism and functional roles of endogenous d-serine in mammalian brains.
22009226 - Phylogenetic and preliminary phenotypic analysis of yeast paqr receptors: potential ant...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current neuropharmacology     Volume:  9     ISSN:  1875-6190     ISO Abbreviation:  Curr Neuropharmacol     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-12-01     Completed Date:  2012-08-23     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101157239     Medline TA:  Curr Neuropharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  376-87     Citation Subset:  -    
Affiliation:
Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Curr Neuropharmacol
Journal ID (publisher-id): CN
ISSN: 1570-159X
ISSN: 1875-6190
Publisher: Bentham Science Publishers Ltd
Article Information
Download PDF
©2011 Bentham Science Publishers Ltd
open-access:
Received Day: 2 Month: 3 Year: 2010
Revision Received Day: 14 Month: 4 Year: 2010
Accepted Day: 30 Month: 4 Year: 2010
Print publication date: Month: 6 Year: 2011
Volume: 9 Issue: 2
First Page: 376 Last Page: 387
ID: 3131728
PubMed Id: 22131946
Publisher Id: CN-9-376
DOI: 10.2174/157015911795596621

Kynurenine Metabolites and Migraine: Experimental Studies and Therapeutic Perspectives
Annamária Fejes1
Árpád Párdutz1
József Toldi2
László Vécsei1*
1Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Hungary
2Department of Physiology, Anatomy and Neuroscience, University of Szeged, Szeged, Hungary
*Address correspondence to this author at the Department of Neurology, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged, Semmelweis street 6, Hungary, H-6725, Tel: +3662545351; Fax: +3662545597; E-mail: vecsei@nepsy.szote.u-szeged.hu

MIGRAINE

Migraine is one of the idiopathic headache syndromes [1], and one of the commonest neurological disorders [2]. Despite intensive research, the exact pathomechanism of migraine is still not fully understood and complete preventive and attack therapy can not always be achieved. Activation of the peripheral and central arms of the trigeminal system (TS) are known to be crucial in the attack [3]. This activation may be related to cortical spreading depression (CSD) or to the activity of distinct areas of the brain stem, known as migraine generators [4, 5].

The fundamental mechanism of the migraine attack involves activation of the trigeminovascular system. Through a trigger mechanism, vasodilatation of the dural and pial blood vessels occurs, which can stimulate the perivascular trigeminal primary nerve endings. The activated nociceptors release neuropeptides at the periphery, including calcitonin gene-related peptide (CGRP), substance P and neurokinin A [6]; the levels of CGRP and substance P are elevated during migraine attacks in humans and in animal migraine models [7]. The released neuropeptides cause sterile neurogenic inflammation in the dura mater, in the course of which the blood vessels further dilate, plasma protein extravasation occurs, the mast cells degranulate and release histamine, and polymorphonuclear leukocytes appear [8]. These reactions can be observed in animal models of migraine too [9, 10]. The released inflammatory substances stimulate the trigeminal first-order neurones, leading to peripheral sensitization [11]. This usually evolves within 30 minutes, and gives rise to a throbbing head pain that is aggravated by activities that increase the intracranial pressure, including physical exercise, bending down, coughing and sneezing [12].

The cell bodies of the trigeminal pseudounipolar first-order neurones are located in the trigeminal ganglion (TG). The peripheral projections of these neurones partially innervate the intracranial pain structures, including the dural and pial blood vessels, the large blood vessels of the brain, the dural sinuses and the dura and pia mater, while the central projections end on the second-order neurones of the trigeminal nucleus caudalis (TNC), located in the medulla and the upper portion of the spinal cord. The activation of these first-order neurones leads to an increase in the glutamate level in the TNC [13] and, presumably via the N-methyl-D-asparate (NMDA) glutamate receptors [14], to activation of the second-order neurones [15]. Besides the NMDA receptors, all the other glutamate receptors are present in the TNC [16], and therefore they can also contribute to this process, which is confirmed by the fact that their antagonists are able to inhibit the increase in the number of c-Fos-immunoreactive (IR) neurones [17] and the evoked potential responses [18] in the TNC. Furthermore, the activation of second-order neurones can be modulated through α7-nicotinic acetylcholine (nACh) receptors, which act presynaptically on the transmission of nociceptive information to the central nervous system [19, 20].

Besides peripheral sensitization, the persistent activation of second-order trigeminal neurones evolves to central sensitization in migraineurs, with the appearance of cutaneous allodynia of the scalp and face [15, 21], when non-nociceptive stimuli produce pain. The central sensitization comprises an exaggerated sensory drive, mediated in part by glutamate receptor activation, since increases in extracellular glutamate are correlated with changes in sensory thresholds on the face of the rat [13]. Moreover, the activated second-order trigeminal neurones have functional connections to other important brain stem centres, such as the nucleus tractus solitarius, which can result in nausea and vomiting. Further activation and sensitization of the TS can provoke the sensitization of the third-order neurones from the thalamus to the cortex, which leads to other symptoms of migraine, including photophobia, phonophobia, osmophobia and allodynia of the extremities [21].

Migraine attacks are casually linked with the activation of distinct brain stem nuclei, known as migraine generators, which include the dorsal raphe nucleus (DRN), the nucleus raphe magnus (NRM), the locus coeruleus (LC) and the periaqueductal grey matter (PAG) [5, 22, 23], which are components of the ascending and descending pain pathways. The importance of these areas in migraine is underlined by the fact that migraine attacks could be induced in human subjects by stimulation of the PAG with an implanted electrode [24]. A possible explanation is that the above-described areas may be dysfunctional [25] and perhaps lose their natural antinociceptive function, resulting in headache. Glutamate appears at this level too since its antagonist can decrease the activity of the NRM [26], and its level is increased after stimulation of the sciatic nerve and mechanical foot shock in the LC [27] or after neuronal stimulation in the PAG [28].

Another potential trigger mechanism of migraine involves CSD. This is a slow continuous spread of excitation, followed by depression [29], and is accompanied by slowly-spreading cortical hypoperfusion [30]. It is widely accepted that CSD is the basis of migraine aura [31], which includes various transient neurologic symptoms, the most common of which are visual symptoms. In the process of CSD, activation of the neuronal apical dendrites [32] and astrocytes [33] seems to be important. The latter can link neuronal and vascular events [34]. Although it is not fully understood how CSD can trigger migraine attacks, under certain experimental conditions in animal models, CSD is able to activate the trigeminovascular afferents [4], increase the persistent blood flow and cause plasma protein extravasation in the dura mater [35] and hence to initiate the above-described sensitization procedures in the TS. Another connection between CSD and trigeminal activation may be glutamate and its receptors [36], which play important roles in the generation and propagation of CSD [37].


ROLE OF GLUTAMATE IN MIGRAINE

Glutamate is known to play an important role in primary afferent neurotransmission and nociception [38], and numerous human and animal studies suggest that glutamate is additionally crucial in the pathomechanism of migraine [39]. Measurements of the level of glutamate in the plasma and platelets in migraine patients led to conflicting results: there have been reports of elevated basal glutamate levels in the plasma and platelets of migraineurs, which are further enhanced during the attacks [40, 41], while other studies have described lower or similar levels to those in control subjects [41, 42]. Elevated levels of glutamate in the cerebrospinal fluid have been measured during attacks in migraineurs, which favours the hypothesis of persistent neuronal hyperexcitability in the disorder [42]. The glutamate receptor antagonists can abolish the aura in patients with familial hemiplegic migraine [43] and headache [44]. Animal and human localization studies have revealed glutamate receptors in the TS [16, 45, 46, 47]. Irritation of the trigeminal nerve results in an increased glutamate level in the TNC [13]. L-Glutamate and NMDA can excite the trigeminothalamic nociceptive neurones [14, 48], and NMDA receptor activation mediates nociceptive transmission in the TNC [14]. The administration of glutamate receptor antagonists mitigated the activation of second-order neurones, i.e. the increase in the number of c-Fos-IR neurones [17, 49], the local blood flow changes [50] and the evoked potential responses [18] in the TNC and the dural plasma protein extravasation [51]. Furthermore, the NMDA receptors in the thalamus contribute to the development and maintenance of inflammation-induced hyperalgesia [52].

Glutamate and its receptors are present in the migraine generators too, and seem to be important from the aspect of nociception. For example, the broad-spectrum excitatory amino acid (EAA) antagonist kynurenic acid (KYNA) can decrease the effect of low-intensity electrical stimulation of the nucleus cuneiformis in the NRM [26], and can reduce the response of the serotoninergic neurones in the DRN [53, 54, 55, 56]. Moreover, electrical stimulation of the sciatic nerve and mechanical foot shock enhanced the rates of glutamate release from the LC [27]. The excitatory effect on the LC of glutamate released from the terminals of the nucleus paragigantocellularis, the main source of glutamate in the LC [57], was inhibited by glutamate receptor antagonists [57, 58]. Finally, in the PAG, the glutamate level was increased after neuronal stimulation [28]. These results suggest that glutamate and its receptors may well be important in the triggering of migraine attacks too, and not merely during headache.

In the generation of CSD, a number of different ion pumps and channels are involved [59], among which NMDA receptors and therefore glutamate seem to play crucial roles: (i) NMDA receptor antagonists can inhibit CSD [60], (ii) glutamate is released during CSD under both in vivo and in vitro conditions [61, 62] and (iii) the administration of glutamate and NMDA can evoke CSD [36, 37]. One rare autosomally inherited subtype of migraine with aura is familial hemiplegic migraine. In patients with this condition, CSD may be triggered more easily presumably because the mutations involved increase the synaptic glutamate level [63].

Overall, it seems that glutamate is one of the key molecules in migraine at many levels of the nervous system. Its modulation may be an important means of understanding the pathomechanisms underlying the attack and it may be of potential therapeutic value in migraine.


KYNURENINE METABOLITES

The oxidative ring opening of tryptophan (TRP) leads to L-kynurenine (L-KYN) and the kynurenine pathway (KP) (Fig. 1). The class of compounds known as kynurenine metabolites comprises the totality of the metabolites of the KP, the central route [64] responsible for around 95% of the TRP metabolism [65]. It takes place in the macrophages and microglial cells, and in part in the astrocytes [66, 67], and gives rise to the formation of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) [68].

The basal compound of the KP is L-KYN, which can cross the blood–brain barrier with the aid of a neutral amino acid carrier [69]. The metabolites of the KP include 3-hydroxykynurenine (3-HK), anthranilic acid (ANA), 3-hydroxyanthranilic acid (3-HA), xanthurenic acid (XA), quinolinic acid (QUIN) and KYNA, all with neuroactive properties [70].

3-HK and 3-HA, generated from L-KYN, can cause neuronal damage, because they can elevate the oxidative stress level by production of free radicals [71, 72] or can provoke primary or secondary excitotoxicity [73, 74]. 3-HK is present in nanomolar concentrations in the mammalian brain, though its level can rise to the micromolar range in several pathological conditions [75]. The content of 3-HA, synthetized from 3-HK and/or ANA, likewise increases in various neurological disorders [76]. 3-HK and 3-HA have been demonstrated to cause the death of cultured neuronal cells [77, 78], the cortical and striatal neurones proving the most vulnerable to the toxic effects of 3-HK [78]. Consequently, these compounds have neurotoxic effects [74].

Transamination of 3-HK leads to XA, this generally being considered part of a detoxification process that reduces the concentration of 3-HK [79]. The role of XA in mammals is not well defined. Under physiological conditions, XA is present in the rat brain at a concentration of about 1 µM; an increase is observed in its level in the urine in an animal model of depression [80]. Administration of high doses of XA to rats seems to induce a degree of sedation and analgesia [81]. XA undergoes vesicular accumulation, is transported by neuronal cells, is present in neuronal circuits and is released via a calcium-dependent process in response to stimulation, these features strongly indicating a physiological role for XA in synaptic signalling [79].

QUIN, from which NAD and NADP are formed [68], resides in the cerebrospinal fluid in nanomolar or low micromolar concentrations [82]. When administered intrastriatally, it causes a significant destruction of neurones [73]; its excitotoxic effect is presumably exerted through agonism of the NMDA receptor [83] or stimulation of the release and inhibition of the uptake of endogenous glutamate [84]. It also induces lipid peroxidation [85, 86] and the production of reactive oxygen species [86]. Changes in the absolute or relative concentration of QUIN play an important role in certain neurodegenerative disorders [75, 87, 88].

In contrast with QUIN, KYNA (4-hydroxyquinoline-2-carboxylic acid) exerts a neuroprotective effect: it is able to prevent the neuronal loss in excitotoxic, ischaemia-induced and neuronal injuries [89, 90]. It is synthesized directly from L-KYN in the astrocytes and neurones [67, 91] enzymatically by the action of kynurenine aminotransferases (KATs) [92, 93], mitochondrial aspartate aminotransferase [94] and hemoperoxidases, or non-enzymatically by reactive oxygen species (ROS) [95]. Beyond this route KYNA can be produced from TRP on an additional pathway by tryptophan aminotransferase and ROS [96, 97]. Similarly to that of QUIN, the concentration of KYNA in the human brain is in the nanomolar range [98], which changes in pathological circumstances, including neurological disorders. The level of KYNA can either decrease or increase in various neurological disorders [75, 87, 99]. KYNA is one of the few known endogenous inhibitors of the EAA receptors, including the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), NMDA and kainate (KA) receptor types at higher concentrations [100, 101, 102]. At around 7.9 μM it can block the NMDA receptor by attaching to its glycine-binding site [101]. As a consequence of its binding to the glutamate-binding site, KYNA may influence the receptors via two mechanisms: in nanomolar to micromolar concentrations, it facilitates the AMPA receptors, whereas at high concentrations, it inhibits the glutamate receptors [103]. It was demonstrated by Rozsa et al. [104] that KYNA in micromolar concentrations exerts a neuroinhibitory effect, while in nanomolar concentrations it behaves as a facilitator in the rat hippocampus. KYNA may therefore play an important role in the regulation (inhibition/excitation) in the neuronal network. The normal concentration of KYNA is too low to influence the EAA receptors, and the published data indicate that, even under pathological conditions, the concentration elevation will not necessarily allow KYNA to influence the co-agonist site of the NMDA receptor [105]. It has also been reported to act as a non-competitive blocker of the α7-nACh receptor [106]. This action, which may play a part in the ability of KYNA to generate a deficit in the sensory system [107, 108], has been suggested to be mediated by its binding to sites located in the N-terminal domain of the α7-nACh receptor subunit [109]. Recent results support the view that the KYNA-sensitive presynaptic α7-nACh receptors inhibit glutamate release at low concentration (30–100 nM) [105, 110]. Thus, the nACh receptors may take part in the inhibitory effects of KYNA at low concentration. KYNA could potentially have therapeutic effects in neurological disorders [75, 111, 112] via the above-described receptor inhibitory effects, but its use as a neuroprotective agent is rather restricted because it has only a very limited ability to cross the blood–brain barrier [69]. The experimental data suggest that peripheral treatment with L-KYN dose-dependently increases the concentration of the neuroprotective KYNA in the brain, offering an opportunity for the treatment of stroke and neurodegenerative disorders [88, 113, 114, 115].

Various studies have identified nACh receptors and subunits in the nociceptors of the TG at the messenger ribonucleic acid (mRNA) and protein levels [116]. The α3ß4 and α4ß2 subtypes of the nACh receptor can presumably be found on the trigeminal free nerve endings [117]. Other studies have reported that the α7-nACh receptor is likely to be present in the TG [116]. These receptors can play a role in the tonic inhibition of spinal pain, which can modulate spinal pain perception [118] and probably reduce neurogenic facial vasodilatation, presumably as a result of the decreased release of CGRP from the trigeminal afferent neurones [119].


KYNURENINE METABOLITES AND MIGRAINE
1.  Effects of Kynurenine Metabolites on First-Order Neurones

It is presumably due in part to the existence of various peripheral mechanism that TRP and some of its metabolites, including KYN, KYNA, QUIN, ANA and XA, administered intraperitoneally, can induce analgesia in both the tail-flick and the hot-plate tests, the degree and duration of analgesia varying, depending on the drug, the dose and the test [81] (Fig. 2). The derivatives of ANA, including N-(3,4-dimethoxycinnamoyl)anthranilic acid (tranilast), N-(2,3-xylyl)anthranilic acid (CI-473, mefenamic acid) and the sodium salt of N-(2,6-dichloro-m-tolyl)anthranilic acid (sodium meclofenamate), probably act at the periphery [120], exerting both anti-inflammatory and analgesic properties, with several mechanisms of action [121, 122, 123]. 3-HA also has anti-inflammatory effects [124].

Numerous data are available in connection with the antinociceptive peripheral effect of KYNA. The intraperitoneal injection of rats with KYNA decreased the pain sensitivity in both the tail-flick and the hot-plate tests [125]. Topical intra-articularly administered KYNA, without signs of systemic side-effects, dose-dependently decreased mechanical allodynia, which manifested 30 min after the injection and the highest dose (400 μg) produced prolonged antinociception and almost total relief of allodynia [126]. A KYNA derivative, the 5,7-dichlorokynurenic acid (5,7-DCK), dose-dependently inhibited the development of the nocifensive behaviour evoked by formalin-induced tissue injury and inflammation, and reversed cold allodynia in the chronic constriction injury model, and tactile allodynia in animals subjected to spinal nerve ligation [127]. In one animal model of trigeminovascular activation after electrical stimulation of the TG, the KAT expression of the dural Schwann cells, mast cells and macrophages was decreased, presumably as a result of release from these cells; at the same time, the content of nitric oxide synthase (NOS)-IR nerve fibres in the dura mater increased, suggesting the release of nitric oxide (NO) at the periphery [128]. In another animal model of trigeminal activation, administration of the NO donor nitroglycerine (NTG), the decrease in the area covered by CGRP-IR fibres was prevented by L-KYN in combination with probenecid (PROB) and a KYNA derivative [129], the most likely explanation being that these compounds blocked the activation of first-order neurones and the consecutive release of CGRP from the nerve endings (Fig. 3). These peripheral effects of KYNA can materialize on glutamate receptors localized at the periphery, including the dorsal root and trigeminal ganglion [130, 131], primary sensory afferents [132, 133], postganglionic sympathetic efferents [134], the temporomandibular joint [135] and Schwann cells [136] or on α7-nACh receptors located at the periphery, e.g. the trigeminal ganglion [116]. The G-protein-coupled receptor-35 (GPR35), recently identified as a receptor for KYNA [137], is expressed within nociceptive pathways, including the DRG and spinal cord, at the mRNA and protein levels [138, 139] and is negatively coupled to adenylate cyclase - cyclic adenosine monophosphate (cAMP) signalling in the DRG neurons, which can modulate nociceptive signalling [139]. KYNA proved able to inhibit the forskolin-stimulated formation of cAMP from cultured rat DRG sensory neurones via the GPR35 receptors and can therefore also modulate nociceptive signalling at the periphery [139].

2.  Effects of Kynurenine Metabolites on Second-Order Neurones

Besides the peripheral effects of the kynurenine metabolites, several studies have confirmed that they can also act on the second-order neurones.

In behavioural examinations the intrathecal (i.t.) injection of KYNA and 7-chlorokynurenic acid (7-CK) produced dose-dependent and reversible analgesic effects in the hot-plate, tail-flick and formalin tests of nociception in mice [140] and in rats [141, 142]. Moreover, the i.t. administration of KYNA and 7-CK suppressed hyperalgesia dose-dependently in rats injected with carrageenan [125, 143], treated with i.t. strychnine [144] or after unilateral partial ligation of the sciatic nerve [145]. In mice treated i.t. with an NMDA receptor agonist, the i.t. co-administered 7-CK inhibited the nociceptive behaviour dose-dependently [146]. Finally, i.t. administration of 5,7-DCK dose-dependently reversed the hyperalgesia in hyperalgesic Mg-deficient rats [147]. However, the injection of 7-CK into the rostral anterior cingulate cortex did not affect formalin-induced acute nociceptive behaviour or electric foot shock-induced conditioned place avoidance [148] and the i.t. infusion of 5,7-DCK failed to block the glycine-induced increased pain response in neuropathic rats made by unilateral partial ligation of the sciatic nerve [149]. These results suggest that the central action of kynurenine metabolites in modulating pain perception does not extend to all brain areas that participate in nociception and is dependent on the receptors that take part in pain transmission.

There is also evidence concerning the antinociceptive effects of kynurenine metabolites at the spinal cord level (Fig. 2). The iontophoric administration of KYNA into the spinal cord of cats, for example, markedly reduced both the cutaneous and the muscular nociceptive responses of a wide dynamic range neurones [150] and the nociceptive responses, irregular spontaneous discharges and C-afferent-induced responses of dorsal horn neurones facilitated by the iontophoretic injection of EAA receptor agonists [151]. Further, the i.t. administration of 7-CK reduced the frequency-dependent potentiation (wind-up) to repeated C-fibre stimulation and the related post-discharges [152], but not the initial responses [153] in the nociceptive neurones located in the dorsal horn of rats. Additionally, single-unit recordings of the responses of dorsal horn neurones to C-, Aδ- and Aβ-fibre stimulation and the wind-up and post-discharge responses of the same cells facilitated by bicuculline were inhibited by 7-CK in intact anaesthetized rats [154]. KYNA pre-administered i.t. significantly reduced the total number of c-Fos-IR neurones increased by carrageenan injection into the rat paw, with a more apparent reduction in laminae I-II and IV-V [125]. In vitro experiments on spinal cord also suggest the antinociceptive effect of KYNA. For example, it blocked the excitation of high-threshold mechanoreceptive units by either cutaneous nerve volleys or mechanical stimulation of the skin, suppressed peripherally evoked responses to innocuous mechanical stimuli in the hamster [155] and blocked the responses to non-nociceptive and nociceptive stimulation of the skin of the leg modulated by motoneurone depolarizations and changes in extracellular potassium concentration in the frog [156].

The second-order nociceptive neurones of the TNC play an important role in the pathomechanism of migraine: the i.t. administration of 7-CK significantly reduced the neuronal mechanoreceptive field size and spontaneous activity increased by neonatal capsaicin treatment in adult rats [157], and intracisternally administered KYNA effectively blocked capsaicin-induced eye wipings [158] (Fig. 3.). After systemic treatment with NTG, a well-known activator of the second-order trigeminal neurones [159], L-KYN combined with PROB attenuated the increase in the number of c-Fos-IR neurones in the TNC [160]. Similarly, at the same location, in the same experimental model, pretreatment with the L-KYN+PROB combination and a KYNA derivative, 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride, mitigated the increase in the number of neuronal NOS- and calmodulin-dependent protein kinase II alpha-IR cells [129, 161]. Since both enzymes may play important roles in trigeminal central sensitization [162, 163], KYNA and its derivatives may exert modulatory effects on this phenomenon. KYNA alone failed to modulate c-Fos activation in the TNC in the same model [164], probably because of its poor ability to cross the blood–brain barrier, in marked contrast with its precursor L-KYN and its derivatives, which cross with ease. In another model of migraine, after electrical stimulation of the trigeminal ganglion, pretreatment with i.p. L-KYN combined with PROB mitigated the increase in the content of c-Fos-IR neurones in the rat TNC [165]. Thus, KYNA and its analogues are able to modulate second-order nociceptors in the TS. The above-described results suggest that kynurenine metabolites may have novel perspectives in the treatment of pain and migraine.

3.  Effects of Kynurenine Metabolites on Migraine Generators

There is abundant evidence to indicate that the kynurenine metabolites are able to influence the functioning of migraine generators located at the brain stem level (Fig. 3).

KYNA reduced the responses of serotoninergic neurones of the DRN that were evoked by phasic auditory stimuli [54], by stimulation of the lateral habenula [53], by local electrical stimulation of afferent terminals [55] and by substance P microinfusion [56]. KYNA can also abolish the activation of neurones in the NRM excited by glutamate administration [166] and by low-intensity electrical stimulation of the mesencephalic nucleus cuneiformis [26], and its injection into the PAG can modulate the excitatory and inhibitory effects of electrical and chemical stimulation of the medial preoptic nucleus of the hypothalamus on the NRM [167]. The kynurenine metabolites can modulate the LC too: for example, intracerebroventricular administration of QUIN increased the unit discharge of LC neurones [168]. However, KYNA was able to inhibit the activation of central noradrenergic neurones in the LC evoked by noxious stimulation such as electrical stimulation of the rat hindpaw [57], non-noxious and noxious cutaneous sensory stimuli [158], electrical stimulation of a rear footpad [169] and sciatic nerve stimulation [58]; noxious effect, i.e. sciatic nerve stimulation provokes activation of the catecholamine metabolism within the LC cells, which is decreased by KYNA [170]. The robust activation of the LC neurones by the direct application of KA, NMDA, AMPA or quisqualate was reduced or completely antagonized by KYNA [58, 171, 172]. KYNA was also able to inhibit the activation of the LC neurones evoked by stimulation of nucleus paragigantocellularis [57], which causes increased levels of EAAs in the LC [57, 58]. Furthermore, 7-CK prevented nociceptive behaviour (tail-flick) and pain-related changes in neuronal activity induced in the rostral ventromedial medulla by glycine or D-serine administration into the ventrolateral PAG [173]; the co-administration of KYNA with morphine in the same area enhanced the acute antinociceptive effects of morphine [174]. These results demonstrate that the kynurenine metabolites, are particularly KYNA and its derivatives, can give rise to antinociceptive effects through their influence on higher brain areas.

4.  Effects of Kynurenine Metabolites on CSD

There are a number of experimental data which suggest that glutamate plays an important role in the phenomenon of CSD. The glutamate level was found to be elevated during CSD [62, 61], glutamate or NMDA was able to trigger CSD [36, 37], and the NMDA, AMPA and KA receptor binding sites were increased 1 hour after the induction of CSD in rat neocortical tissues, which may be responsible for the delayed excitatory phase after it [175]. On the other hand, NMDA receptor antagonists, including the non-competitive channel blocking antagonists and competitive glutamate-recognition site antagonists, can inhibit the initiation, propagation, amplitude, frequency and susceptibility of CSD, whereas the non-NMDA receptor antagonists can not [60]. Those of the NMDA receptor antagonists that act on the NR2-B subunit may selectively inhibit the initiation and propagation of CSD [176]. These data strongly suggest that only the NMDA receptors play a role in CSD. This is further supported by the results of studies, which examined the effects of Mg2+ (an NMDA receptor channel blocker), and found that it can selectively inhibit glutamate-induced spreading depression (SD) [177], and that the Mg2+ depletion, which releases the voltage-dependent block of the NMDA receptor channel, induces CSD [178].

Few studies have been made of the link between CSD and the kynurenine metabolites, and the available results are conflicting (Fig. 3). It has been established that unilateral, consecutive CSDs result in ipsilateral increases in KYNA levels in the frontal, parietal and occipital cortices [179]. Some studies have indicated that KYNA can inhibit SD under certain conditions in the turtle cerebellum [37] and in the adult rat neocortex [180], while others were not able to detect such an effect in the CA1 neurones of the rat hippocampus [181] or in neocortical brain slices [182]. Interestingly, QUIN concentration-dependently suppressed the elicitation of CSD in the cerebral cortex of the rat, presumably because of NMDA receptor desensitization [183, 184]. Since a wide range of NMDA receptor antagonists are able to inhibit electrical CSD, it is highly likely that KYNA can also do this. In experiments where KYNA was ineffective, ischaemic SD was elicited by O2/glucose deprivation, in which glutamate probably does not play a role, whereas it seems to be crucial in potassium-triggered SD. Consequently, KYNA and its derivatives may be of promise in the therapy against migraine aura, where important parts are played by the ion pumps and hence the ion currents.


CONCLUSIONS

Overall, the involvement of KP metabolites (particularly KYNA and its derivatives) at various sites of nociception and in migraine is of appreciable importance. The evidence points to the ability of these compounds to modulate migraine at several levels of the related neuronal areas, including the primary nociceptive afferents, the neurones in the TNC, and the migraine generators, and presumably at the CSD level too. KYNA and its derivatives may therefore offer new opportunities in the therapy of migraine and other diseases related to trigeminal nociception.


ACKNOWLEDGEMENTS

This work was supported by Teller Ede funding (NAP-BIO-06-BAYBIOSZ), ETT (026-04), TÁMOP-4 (2.2-08/1/2008-0002) and cNEUPRO (LSHM-CT-2007-037950) grants.

Thanks are due to David Durham for linguistic correction of the manuscript.


REFERENCES
1. The International Classification of Headache Disorders: 2nd edCephalalgiaYear: 200424Suppl 1916014979299
2. Lipton RB,Stewart WF,Diamond S,Diamond ML,Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study IIHeadacheYear: 200141764665711554952
3. Moskowitz MA. Defining a pathway to discovery from bench to bedside: the trigeminovascular system and sensitizationHeadacheYear: 200848568869018471111
4. Moskowitz MA,Nozaki K,Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanismsJ. NeurosciYear: 1993133116711778382735
5. Weiller C,May A,Limmroth V,Juptner M,Kaube H,Schayck RV,Coenen HH,Diener HC. Brain stem activation in spontaneous human migraine attacksNat. MedYear: 1995176586607585147
6. Ebersberger A,Averbeck B,Messlinger K,Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitroNeuroscienceYear: 199989390190710199623
7. Goadsby PJ,Edvinsson L,Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnn. NeurolYear: 19882321931962454066
8. Williamson DJ,Hargreaves RJ. Neurogenic inflammation in the context of migraineMicrosc. Res. TechYear: 200153316717811301492
9. Markowitz S,Saito K,Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headacheCephalalgiaYear: 19888283913401921
10. Williamson DJ,Hargreaves RJ,Hill RG,Shepheard SL. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized ratCephalalgiaYear: 19971745185249209773
11. Strassman AM,Raymond SA,Burstein R. Sensitization of meningeal sensory neurons and the origin of headachesNatureYear: 199638466095605648955268
12. Blau JN,Dexter SL. The site of pain origin during migraine attacksCephalalgiaYear: 1981131431477346182
13. Oshinsky ML,Luo J. Neurochemistry of trigeminal activation in an animal model of migraineHeadacheYear: 200646Suppl 1S39S4416927963
14. Wang XM,Mokha SS. Opioids modulate N-methyl-D-aspartic acid (NMDA)-evoked responses of trigeminothalamic neuronsJ. NeurophysiolYear: 1996763209320968890319
15. Burstein R,Yamamura H,Malick A,Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neuronsJ. NeurophysiolYear: 19987929649829463456
16. Tallaksen-Greene SJ,Young AB,Penney JB,Beitz AJ. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the ratNeurosci. LettYear: 1992141179831324445
17. Mitsikostas DD,Sanchez del RM,Waeber C,Huang Z,Cutrer FM,Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalisBr. J. PharmacolYear: 1999127362363010401552
18. Storer RJ,Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptorsNeuroscienceYear: 19999041371137610338304
19. McGehee DS,Heath MJ,Gelber S,Devay P,Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptorsScienceYear: 19952695231169216967569895
20. Gray R,Rajan AS,Radcliffe KA,Yakehiro M,Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotineNatureYear: 199638366027137168878480
21. Burstein R,Yarnitsky D,Goor-Aryeh I,Ransil BJ,Bajwa ZH. An association between migraine and cutaneous allodyniaAnn. NeurolYear: 200047561462410805332
22. Lance JW,Lambert GA,Goadsby PJ,Duckworth JW. Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraineHeadacheYear: 19832362582656643036
23. Diener HC. Positron emission tomography studies in headacheHeadacheYear: 199737106226259439081
24. Raskin NH,Hosobuchi Y,Lamb S. Headache may arise from perturbation of brainHeadacheYear: 19872784164203667258
25. Welch KM,Nagesh V,Aurora SK,Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?HeadacheYear: 200141762963711554950
26. Richter RC,Behbehani MM. Evidence for glutamic acid as a possible neurotransmitter between the mesencephalic nucleus cuneiformis and the medullary nucleus raphe magnus in the lightly anesthetized ratBrain ResYear: 199154422792861674895
27. Singewald N,Schneider C,Philippu A. Effects of neuroactive compounds, noxious and cardiovascular stimuli on the release of amino acids in the rat locus coeruleusNeurosci. LettYear: 1994180155587877762
28. Renno WM,Alkhalaf M,Mousa A,Kanaan RA. A comparative study of excitatory and inhibitory amino acids in three different brainstem nucleiNeurochem. ResYear: 200833115015917940899
29. Leao AAP. Spreading depression of activity in cerebral cortexJ. NeurophysiolYear: 194476359390
30. Lauritzen M,Jorgensen MB,Diemer NH,Gjedde A,Hansen AJ. Persistent oligemia of rat cerebral cortex in the wake of spreading depressionAnn. NeurolYear: 19821254694747181451
31. Lauritzen M. Pathophysiology of the migraine auraThe spreading depression theory. BrainYear: 1994117Pt 1199210
32. Henning EC,Meng X,Fisher M,Sotak CH. Visualization of cortical spreading depression using manganese-enhanced magnetic resonance imagingMagn Reson. MedYear: 200553485185715799040
33. Peters O,Schipke CG,Hashimoto Y,Kettenmann H. Different mechanisms promote astrocyte Ca2+ waves and spreading depression in the mouse neocortexJ. NeurosciYear: 200323309888989614586018
34. Chuquet J,Hollender L,Nimchinsky EA. High-resolution in vivo imaging of the neurovascular unit during spreading depressionJ. NeurosciYear: 200727154036404417428981
35. Bolay H,Reuter U,Dunn AK,Huang Z,Boas DA,Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine modelNat. MedYear: 20028213614211821897
36. Ayata C,Moskowitz MA. Cortical spreading depression confounds concentration-dependent pial arteriolar dilation during N-methyl-D-aspartate superfusionAm. J. Physiol Heart Circ. PhysiolYear: 20062905H1837H184116299263
37. Lauritzen M,Rice ME,Okada Y,Nicholson C. Quisqualate, kainate and NMDA can initiate spreading depression in the turtle cerebellumBrain ResYear: 198847523173272905624
38. Dickenson AH,Chapman V,Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cordGen. PharmacolYear: 19972856336389184794
39. Vikelis M,Mitsikostas DD. The role of glutamate and its receptors in migraineCNS. Neurol. Disord. Drug TargetsYear: 20076425125717691981
40. Ferrari MD,Odink J,Bos KD,Malessy MJ,Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraineNeurologyYear: 19904010158215861977102
41. Cananzi AR,D'Andrea G,Perini F,Zamberlan F,Welch KM. Platelet and plasma levels of glutamate and glutamine in migraine with and without auraCephalalgiaYear: 19951521321357641248
42. Martinez F,Castillo J,Rodriguez JR,Leira R,Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacksCephalalgiaYear: 199313289938098663
43. Kaube H,Herzog J,Kaufer T,Dichgans M,Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamineNeurologyYear: 200055113914110891926
44. Sang CN,Ramadan NM,Wallihan RG,Chappell AS,Freitag FG,Smith TR,Silberstein SD,Johnson KW,Phebus LA,Bleakman D,Ornstein PL,Arnold B,Tepper SJ,Vandenhende F. LY293558, a novel AMPA/GluR5 an-tagonist, is efficacious and well-tolerated in acute migraineCephalalgiaYear: 200424759660215196302
45. Watanabe M,Mishina M,Inoue Y. Distinct gene expression of the N-methyl-D-aspartate receptor channel subunit in peripheral neurons of the mouse sensory ganglia and adrenal glandNeurosci. LettYear: 19941651-21831868015722
46. Sahara Y,Noro N,Iida Y,Soma K,Nakamura Y. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neuronsJ. NeurosciYear: 19971717661166209254673
47. Quartu M,Serra MP,Ambu R,Lai ML,Del FM. AMPA-type glutamate receptor subunits 2/3 in the human trigeminal sensory ganglion and subnucleus caudalis from prenatal ages to adulthoodMech. Ageing DevYear: 2002123546347111796131
48. Hill RG,Salt TE. An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuliJ. PhysiolYear: 198232765786288930
49. Mitsikostas DD,Sanchez del RM,Waeber C,Moskowitz MA,Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalisPainYear: 1998761-22392489696479
50. Goadsby PJ,Classey JD. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flowBrain ResYear: 20008751-211912410967305
51. Filla SA,Winter MA,Johnson KW,Bleakman D,Bell MG,Bleisch TJ,Castano AM,Clemens-Smith A,del PM,Dieckman DK,Dominguez E,Escribano A,Ho KH,Hudziak KJ,Katofiasc MA,Martinez-Perez JA,Mateo A,Mathes BM,Mattiuz EL,Ogden AM,Phebus LA,Stack DR,Stratford RE,Ornstein PL. Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraineJ. Med. ChemYear: 200245204383438612238915
52. Kolhekar R,Murphy S,Gebhart GF. Thalamic NMDA receptors modulate inflammation-produced hyperalgesia in the ratPainYear: 199771131409200171
53. Kalen P,Strecker RE,Rosengren E,Bjorklund A. Regulation of striatal serotonin release by the lateral habenula-dorsal raphe pathway in the rat as demonstrated by in vivo microdialysis: role of excitatory amino acids and GABABrain ResYear: 19894921-21872022473826
54. Levine ES,Jacobs BL. Neurochemical afferents controlling the activity of serotonergic neurons in the dorsal raphe nucleus: microiontophoretic studies in the awake catJ. NeurosciYear: 19921210403740441357117
55. Pinnock RD. Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitroBrain ResYear: 19925831-22372461354563
56. Valentino RJ,Bey V,Pernar L,Commons KG. Substance P Acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activityJ. NeurosciYear: 200323187155715912904475
57. Ennis M,Aston-Jones G. Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brainJ. NeurosciYear: 1988810364436573193175
58. Ennis M,Aston-Jones G,Shiekhattar R. Activation of locus coeruleus neurons by nucleus paragigantocellularis or noxious sensory stimulation is mediated by intracoerulear excitatory amino acid neurotransmissionBrain ResYear: 19925981-21851951336704
59. Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarizationPhysiol. RevYear: 20018131065109611427692
60. Nellgard B,Wieloch T. NMDA-receptor blockers but not NBQX, an AMPA-receptor antagonist, inhibit spreading depression in the rat brainActa Physiol. ScandYear: 199214644975031283483
61. Fabricius M,Jensen LH,Lauritzen M. Microdialysis of interstitial amino acids during spreading depression and anoxic depolarization in rat neocortexBrain ResYear: 19936121-261698330214
62. Basarsky TA,Feighan D,MacVicar BA. Glutamate release through volume-activated channels during spreading depressionJ. NeurosciYear: 199919156439644510414972
63. Pietrobon D. Familial hemiplegic migraineNeurotherapeuticsYear: 20074227428417395138
64. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathwayScand. J. Clin. Lab. InvestYear: 19741361186
65. Tyce GM. Origin and metabolism of serotoninJ. Cardiovasc. PharmacolYear: 199016Suppl 3S1S71369709
66. Guillemin GJ,Kerr SJ,Pemberton LA,Smith DG,Smythe GA,Armati PJ,Brew BJ. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatmentJ. Interferon Cytokine ResYear: 200121121097110111798468
67. Guillemin GJ,Smith DG,Smythe GA,Armati PJ,Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophagesAdv. Exp. Med. BiolYear: 200352710511215206722
68. Beadle GW,Mitchell HK,Nyc JF. Kynurenine as an Intermediate in the Formation of Nicotinic Acid from Tryptophane by NeurosporaProc. Natl. Acad. Sci. USAYear: 194733615515816588735
69. Fukui S,Schwarcz R,Rapoport SI,Takada Y,Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolismJ. NeurochemYear: 1991566200720171827495
70. Lapin IP. Stimulant and convulsive effects of kynurenines injected into brain ventricles in miceJ. Neural TransmYear: 19784213743641543
71. Dykens JA,Sullivan SG,Stern A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinateBiochem. PharmacolYear: 19873622112172949752
72. Eastman CL,Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenineNeurochem. ResYear: 19901511110111072089269
73. Guidetti P,Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatumEur. J. NeurosciYear: 199911113857386310583474
74. Jhamandas K,Boegman RJ,Beninger RJ,Bialik M. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolitesBrain ResYear: 19905291-21851912149296
75. Stone TW,Mackay GM,Forrest CM,Clark CJ,Darlington LG. Tryptophan metabolites and brain disordersClin. Chem. Lab MedYear: 200341785285912940508
76. Pearson SJ,Reynolds GP. Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathyJ. ChromatogrYear: 19915651-24364401874889
77. Okuda S,Nishiyama N,Saito H,Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenineProc. Natl. Acad. Sci. USAYear: 1996932212553125588901620
78. Okuda S,Nishiyama N,Saito H,Katsuki H. 3-Hydroxy-kynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivityJ. NeurochemYear: 19987012993079422375
79. Gobaille S,Kemmel V,Brumaru D,Dugave C,Aunis D,Maitre M. Xanthurenic acid distribution, transport, accumulation and release in the rat brainJ. NeurochemYear: 2008105398299318182052
80. Zheng S,Yu M,Lu X,Huo T,Ge L,Yang J,Wu C,Li F. Urinary metabonomic study on biochemical changes in chronic unpredictable mild stress model of depressionClin. Chim. ActaYear: 20104113-420420919913000
81. Heyliger SO,Goodman CB,Ngong JM,Soliman KF. The analgesic effects of tryptophan and its metabolites in the ratPharmacol. ResYear: 19983842432509774487
82. Schwarcz R,Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunitiesJ. Pharmacol. Exp. TherYear: 2002303111012235226
83. de Carvalho LP,Bochet P,Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunitsNeurochem. IntYear: 19962844454528740453
84. Tavares RG,Tasca CI,Santos CE,Alves LB,Porciuncula LO,Emanuelli T,Souza DO. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytesNeurochem. IntYear: 200240762162711900857
85. Rios C,Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenatesNeurochem. ResYear: 19911610113911431686636
86. Behan WM,McDonald M,Darlington LG,Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenylBr. J. PharmacolYear: 199912881754176010588931
87. Vecsei L,Schwab F. [Kynurenine and its metabolites in nervous system diseases]Orv. HetilYear: 199213329180318071386152
88. Vecsei L,Beal MF. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectivesBiol. PsychiatryYear: 19963912106110638780845
89. Smith DH,Okiyama K,Thomas MJ,McIntosh TK. Effects of the excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injuryJ. NeurosciYear: 19931312538353928254381
90. Gigler G,Szenasi G,Simo A,Levay G,Harsing LG Jr.,Sas K,Vecsei L,Toldi J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbilsEur. J. PharmacolYear: 20075641-311612217407777
91. Guillemin GJ,Cullen KM,Lim CK,Smythe GA,Garner B,Kapoor V,Takikawa O,Brew BJ. Characterization of the kynurenine pathway in human neuronsJ. NeurosciYear: 20072747128841289218032661
92. Guidetti P,Okuno E,Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and IIJ. Neurosci. ResYear: 19975034574659364331
93. Yu P,Li Z,Zhang L,Tagle DA,Cai T. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT familyGeneYear: 200636511111816376499
94. Guidetti P,Amori L,Sapko MT,Okuno E,Schwarcz R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brainJ. NeurochemYear: 2007102110311117442055
95. Zsizsik BK,Hardeland R. Formation of kynurenic and xanthurenic acids from kynurenine and 3-hydroxykynurenine in the dinoflagellate Lingulodinium polyedrum: role of a novel, oxidative pathwayComp. Biochem. Physiol C. Toxicol. PharmacolYear: 2002133338339212379423
96. Politi V,Lavaggi MV,Di SG,Margonelli A. Indole-3-pyruvic acid as a direct precursor of kynurenic acidAdv. Exp. Med. BiolYear: 19912945155181772085
97. Politi V,D'Alessio S,Di SG,De LG. Antioxidant properties of indole-3-pyruvic acidAdv. Exp. Med. BiolYear: 19963982912988906280
98. Turski WA,Nakamura M,Todd WP,Carpenter BK,Whetsell WO Jr,Schwarcz R. Identification and quantification of kynurenic acid in human brain tissueBrain ResYear: 19884541-21641693409000
99. Hartai Z,Klivenyi P,Janaky T,Penke B,Dux L,Vecsei L. Kynurenine metabolism in multiple sclerosisActa Neurol. ScandYear: 20051122939616008534
100. Birch PJ,Grossman CJ,Hayes AG. Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptorsEur. J. PharmacolYear: 198815123133152901972
101. Kessler M,Terramani T,Lynch G,Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonistsJ. NeurochemYear: 1989524131913282538568
102. Bertolino M,Vicini S,Costa E. Kynurenic acid inhibits the activation of kainic and N-methyl-D-aspartic acid-sensitive ionotropic receptors by a different mechanismNeuropharmacologyYear: 19892854534572471112
103. Prescott C,Weeks AM,Staley KJ,Partin KM. Kynurenic acid has a dual action on AMPA receptor responsesNeurosci. LettYear: 20064021-210811216644124
104. Rozsa E,Robotka H,Vecsei L,Toldi J. The Janus-face kynurenic acidJ. Neural TransmYear: 200811581087109118446262
105. Carpenedo R,Pittaluga A,Cozzi A,Attucci S,Galli A,Raiteri M,Moroni F. Presynaptic kynurenate-sensitive receptors inhibit glutamate releaseEur. J. NeurosciYear: 200113112141214711422455
106. Hilmas C,Pereira EF,Alkondon M,Rassoulpour A,Schwarcz R,Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implicationsJ. NeurosciYear: 200121197463747311567036
107. Shepard PD,Joy B,Clerkin L,Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the ratNeuropsychopharmacologyYear: 20032881454146212700696
108. Chess AC,Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned respondingBehav. Brain ResYear: 2006170232633216621049
109. Pereira EF,Hilmas C,Santos MD,Alkondon M,Maelicke A,Albuquerque EX. Unconventional ligands and modulators of nicotinic receptorsJ. NeurobiolYear: 200253447950012436414
110. Marchi M,Risso F,Viola C,Cavazzani P,Raiteri M. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminalsJ. NeurochemYear: 20028061071107811953457
111. Nemeth H,Toldi J,Vecsei L. Role of kynurenines in the central and peripheral nervous systemsCurr. Neurovasc. ResYear: 20052324926016181118
112. Vamos E,Pardutz A,Klivenyi P,Toldi J,Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotectionJ. Neurol. SciYear: 20092831-2212719268309
113. Swartz KJ,During MJ,Freese A,Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptorsJ. NeurosciYear: 1990109296529732168940
114. Vecsei L,Miller J,MacGarvey U,Beal MF. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brainBrain Res. BullYear: 19922822332381596743
115. Zadori D,Klivenyi P,Vamos E,Fulop F,Toldi J,Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategiesJ. Neural TransmYear: 2009116111403140919618107
116. Liu L,Chang GQ,Jiao YQ,Simon SA. Neuronal nicotinic acetylcholine receptors in rat trigeminal gangliaBrain ResYear: 199880922382459853116
117. Alimohammadi H,Silver WL. Evidence for nicotinic acetylcholine receptors on nasal trigeminal nerve endings of the ratChem. SensesYear: 2000251616610667995
118. Matsumoto M,Xie W,Inoue M,Ueda H. Evidence for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferentsMol. PainYear: 200734118088441
119. Just S,Arndt K,Doods H. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changesNeurosci. LettYear: 20053811-212012415882801
120. Brogden RN. Non-steroidal anti-inflammatory analgesics other than salicylatesDrugsYear: 198632Suppl 427453552584
121. Winder CV,Wax J,Scotti L,Scherrer RA,Jones EM,Short FW. Anti-inflammatory, antipyretic and antinociceptive properties of N-(2,3-xylyl)anthranilic acid (mefenamic acid)J. Pharmacol. Exp. TherYear: 196213340541814001132
122. Honorato PJ,Marti MR,Imizcoz Barriola JL. Meclofenamate sodium in the treatment of post-traumatic edema. Report of a controlled double-blind studyArzneimittelforschungYear: 1983334A6636676349654
123. Inglis JJ,Criado G,Andrews M,Feldmann M,Williams RO,Selley ML. The anti-allergic drug, N-(3',4'-dimethoxy-cinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritisRheumatology (Oxford)Year: 20074691428143217644821
124. Pae HO,Oh GS,Lee BS,Rim JS,Kim YM,Chung HT. 3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cellsAtherosclerosisYear: 2006187227428416246346
125. Zhang YQ,Ji GC,Wu GC,Zhao ZQ. Kynurenic acid enhances electroacupuncture analgesia in normal and carrageenan-injected ratsBrain ResYear: 2003966230030712618353
126. Mecs L,Tuboly G,Nagy E,Benedek G,Horvath G. The peripheral antinociceptive effects of endomorphin-1 and kynurenic acid in the rat inflamed joint modelAnesth. AnalgYear: 200910941297130419762760
127. Christoph T,Reissmuller E,Schiene K,Englberger W,Chizh BA. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanismsBrain ResYear: 200510481-221822715922311
128. Knyihar-Csillik E,Chadaide Z,Okuno E,Krisztin-Peva B,Toldi J,Varga C,Molnar A,Csillik B,Vecsei L. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglionExp. NeurolYear: 2004186224224715026260
129. Vamos E,Fejes A,Koch J,Tajti J,Fulop F,Toldi J,Pardutz A,Vecsei L. Kynurenate derivative attenuates the nitroglycerin-induced camkiialpha and CGRP expression changesHeadacheYear: 20095058344319925620
130. Shigemoto R,Ohishi H,Nakanishi S,Mizuno N. Expression of the mRNA for the rat NMDA receptor (NMDAR1) in the sensory and autonomic ganglion neuronsNeurosci. LettYear: 19921441-22292321436707
131. Sato K,Kiyama H,Park HT,Tohyama M,AMPA KA. NMDA receptors are expressed in the rat DRG neuronesNeuroreportYear: 1993411126312658219025
132. Liu H,Wang H,Sheng M,Jan LY,Jan YN,Basbaum AI. Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the spinal cord dorsal hornProc. Natl. Acad. Sci. USAYear: 19949118838383878078891
133. Carlton SM,Hargett GL,Coggeshall RE. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skinNeurosci. LettYear: 1995197125288545047
134. Coggeshall RE,Carlton SM. Evidence for an inflammation-induced change in the local glutamatergic regulation of postganglionic sympathetic efferentsPainYear: 199983216316810534587
135. Cairns BE,Sessle BJ,Hu JW. Evidence that excitatory amino acid receptors within the temporomandibular joint region are involved in the reflex activation of the jaw musclesJ. NeurosciYear: 19981819805680649742172
136. Kinkelin I,Brocker EB,Koltzenburg M,Carlton SM. Localization of ionotropic glutamate receptors in peripheral axons of human skinNeurosci. LettYear: 2000283214915210739897
137. Wang J,Simonavicius N,Wu X,Swaminath G,Reagan J,Tian H,Ling L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35J. Biol. ChemYear: 200628131220212202816754668
138. Taniguchi Y,Tonai-Kachi H,Shinjo K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35FEBS LettYear: 2006580215003500816934253
139. Ohshiro H,Tonai-Kachi H,Ichikawa K. GPR35 is a functional receptor in rat dorsal root ganglion neuronsBiochem. Biophys. Res. CommunYear: 2008365234434817996730
140. Nasstrom J,Karlsson U,Post C. Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in miceEur. J. PharmacolYear: 1992212121291313371
141. Kristensen JD,Post C,Gordh T Jr,Svensson BA. Spinal cord morphology and antinociception after chronic intrathecal administration of excitatory amino acid antagonists in the ratPainYear: 19935433093168233545
142. Chapman V,Dickenson AH. Time-related roles of excitatory amino acid receptors during persistent noxiously evoked responses of rat dorsal horn neuronesBrain ResYear: 19957031-245508719614
143. Ren K,Williams GM,Hylden JL,Ruda MA,Dubner R. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in ratsEur. J. PharmacolYear: 199221922352431358641
144. Yaksh TL. Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonistsPainYear: 19893711111232542867
145. Yamamoto T,Yaksh TL. Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve Excitatory amino acid antagonistsPainYear: 19924911211281594273
146. Tan-No K,Esashi A,Nakagawasai O,Niijima F,Furuta S,Sato T,Satoh S,Yasuhara H,Tadano T. Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-D-aspartate receptor ion-channel complex acting on the glycine recognition siteJ. Pharmacol. SciYear: 20071041394517452810
147. Begon S,Pickering G,Eschalier A,Mazur A,Rayssiguier Y,Dubray C. Role of spinal NMDA receptors, protein kinase C and nitric oxide synthase in the hyperalgesia induced by magnesium deficiency in ratsBr. J. PharmacolYear: 200113461227123611704642
148. Ren WH,Guo JD,Cao H,Wang H,Wang PF,Sha H,Ji RR,Zhao ZQ,Zhang YQ. Is endogenous D-serine in the rostral anterior cingulate cortex necessary for pain-related negative affect?J. NeurochemYear: 20069661636164716476080
149. Simpson RK Jr,Gondo M,Robertson CS,Goodman JC. Reduction in the mechanonociceptive response by intrathecal administration of glycine and related compoundsNeurochem. ResYear: 19962110122112268923484
150. Song XJ,Zhao ZQ. Differential effects of NMDA and non-NMDA receptor antagonists on spinal cutaneous vs muscular nociception in the catNeuroreportYear: 19934117208095819
151. Song XJ,Zhao ZQ. NMDA and non-NMDA receptors mediating nociceptive and non-nociceptive transmission in spinal cord of catZhongguo Yao Li Xue BaoYear: 19931464814858010042
152. Dickenson AH,Aydar E. Antagonism at the glycine site on the NMDA receptor reduces spinal nociception in the ratNeurosci. LettYear: 19911211-22632661826945
153. Chapman V,Dickenson AH. The combination of NMDA antagonism and morphine produces profound antinociception in the rat dorsal hornBrain ResYear: 199257323213231387029
154. Reeve AJ,Dickenson AH,Kerr NC. Spinal effects of bicuculline: modulation of an allodynia-like state by an A1-receptor agonist, morphine, and an NMDA-receptor antagonistJ. NeurophysiolYear: 1998793149415079497427
155. Schneider SP,Perl ER. Synaptic mediation from cutaneous mechanical nociceptorsJ. NeurophysiolYear: 19947226126217983523
156. Holohean AM,Vega JL,Hackman JC,Davidoff RA. Excitatory transmitters, ventral root potentials and [K+]o in the isolated frog leg-spinal cord preparationNeurosci. LettYear: 1988951-31731782465509
157. Chiang CY,Hu JW,Sessle BJ. NMDA receptor involvement in neuroplastic changes induced by neonatal capsaicin treatment in trigeminal nociceptive neuronsJ. NeurophysiolYear: 1997785279928039356428
158. Hajos M,Engberg G. A role of excitatory amino acids in the activation of locus coeruleus neurons following cutaneous thermal stimuliBrain ResYear: 19905211-23253282169960
159. Tassorelli C,Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the ratBrain ResYear: 19956821-21671817552308
160. Knyihar-Csillik E,Toldi J,Mihaly A,Krisztin-Peva B,Chadaide Z,Nemeth H,Fenyo R,Vecsei L. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine modelJ. Neural TransmYear: 2007114441742116897600
161. Vamos E,Pardutz A,Varga H,Bohar Z,Tajti J,Fulop F,Toldi J,Vecsei L. l-kynurenine combined with probenecid and the novel synthetic kynurenic acid derivative attenuate nitroglycerin-induced nNOS in the rat caudal trigeminal nucleusNeuropharmacologyYear: 200957442542919580819
162. Pardutz A,Krizbai I,Multon S,Vecsei L,Schoenen J. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalisNeuroreportYear: 200011143071307511043526
163. Pardutz A,Hoyk Z,Varga H,Vecsei L,Schoenen J. Oestrogen-modulated increase of calmodulin-dependent protein kinase II (CamKII) in rat spinal trigeminal nucleus after systemic nitroglycerinCephalalgiaYear: 2007271465317212683
164. Knyihar-Csillik E,Mihaly A,Krisztin-Peva B,Robotka H,Szatmari I,Fulop F,Toldi J,Csillik B,Vecsei L. The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acidNeurosci. ResYear: 200861442943218541319
165. Knyihar-Csillik E,Toldi J,Krisztin-Peva B,Chadaide Z,Nemeth H,Fenyo R,Vecsei L. Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecidNeurosci. LettYear: 2007418212212617382471
166. Murphy AZ,Behbehani MM. Electrophysiological characterization of the projection from the nucleus raphe magnus to the lateral reticular nucleus: possible role of an excitatory amino acid in synaptic activationBrain ResYear: 1993606168788462005
167. Jiang M,Behbehani MM. Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal grayPainYear: 200194213914711690727
168. Ping HX,Wu HQ,Liu GQ. Modulation of neuronal activity of locus coeruleus in rats induced by excitatory amino acidsZhongguo Yao Li Xue BaoYear: 19901131931952087991
169. Akaoka H,ston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid inputJ. NeurosciYear: 19911112383038391683899
170. Brun P,Suaud-Chagny MF,Lachuer J,Gonon F,Buda M. Catecholamine Metabolism in Locus Coeruleus Neurons: A Study of its Activation by Sciatic Nerve Stimulation in the RatEur. J. NeurosciYear: 19913539740612106179
171. Olpe HR,Steinmann MW,Brugger F,Pozza MF. Excitatory amino acid receptors in rat locus coeruleus. An extracellular in vitro studyNaunyn Schmiedebergs Arch. PharmacolYear: 198933933123142566932
172. Nieber K,Poelchen W,Illes P. Role of ATP in fast excitatory synaptic potentials in locus coeruleus neurones of the ratBr. J. PharmacolYear: 199712234234309351497
173. Palazzo E,Guida F,Migliozzi A,Gatta L,Marabese I,Luongo L,Rossi C,de NV,Fernandez-Sanchez E,Soukupova M,Zafra F,Maione S. Intraperiaqueductal gray glycine and D-serine exert dual effects on rostral ventromedial medulla ON- and OFF-cell activity and thermoceptive threshold in the ratJ. NeurophysiolYear: 200910263169317919776366
174. Morgan MM,Bobeck EN,Ingram SL. Glutamate modulation of antinociception, but not tolerance, produced by morphine microinjection into the periaqueductal gray of the ratBrain ResYear: 20091295596619664608
175. Haghir H,Kovac S,Speckmann EJ,Zilles K,Gorji A. Patterns of neurotransmitter receptor distributions following cortical spreading depressionNeuroscienceYear: 200916341340135219665048
176. Faria LC,Mody I. Protective effect of ifenprodil against spreading depression in the mouse entorhinal cortexJ. NeurophysiolYear: 20049242610261415201313
177. Van Harreveld A,Fifkova E. Mechanisms involved in spreading depressionJ. NeurobiolYear: 1973443753874724814
178. Mody I,Lambert JD,Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slicesJ. NeurophysiolYear: 19875738698883031235
179. Kiss C,Shepard PD,Bari F,Schwarcz R. Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortexBrain ResYear: 200410021-212913514988042
180. Vilagi I,Klapka N,Luhmann HJ. Optical recording of spreading depression in rat neocortical slicesBrain ResYear: 2001898228829611306015
181. Obeidat AS,Jarvis CR,Andrew RD. Glutamate does not mediate acute neuronal damage after spreading depression induced by O2/glucose deprivation in the hippocampal sliceJ. Cereb. Blood Flow MetabYear: 200020241242210698080
182. Jarvis CR,Anderson TR,Andrew RD. Anoxic depolarization mediates acute damage independent of glutamate in neocortical brain slicesCereb. CortexYear: 200111324925911230096
183. Obrenovitch TP. Quinolinic acid accumulation during neuroinflammation. Does it imply excitotoxicity? Ann. N. Y. Acad. SciYear: 2001939110 (neuroprotective agents: fifth international conference). 11462760
184. Obrenovitch TP,Urenjak J. Accumulation of quinolinic acid with neuroinflammation: does it mean excitotoxicity?Adv. Exp. Med. BiolYear: 200352714715415206727

Article Categories:
  • Article

Keywords: Keywords Cortical spreading depression, glutamate, kynurenic acid, kynurenine metabolites, migraine, migraine generators, trigeminal system..

Previous Document:  Carbohydrate reward and psychosis: an explanation for neuroleptic induced weight gain and path to im...
Next Document:  Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines.